PHEBRA WORLDWIDE
Return to Product Listing

Landiolol Hydrochloride Powder for Injection for Infusion (Rapiblyk®)

Rapiblyk® Powder for Injection for Infusion contains landiolol hydrochloride 300 mg, equivalent to 280 mg landiolol.

Indication:
Rapiblyk® is indicated in adults for: • Supraventricular tachycardia and for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short acting agent is desirable. • non-compensatory sinus tachycardia where, in the physician’s judgment the rapid heart rate requires specific intervention. Rapiblyk® is not intended for use in chronic settings.

  • Strength: 300mg vial landiolol hydrochloride powder for injection for infusion, equivalent to 280mg landiolol
  • Package: 1 x 50mL glass vial
  • Phebra Code: INJ206
  • Pack Size: 1

Resources:

Rapiblyk® Mode of Action Video

To view Rapiblyk® mode of action video, click the link and enter your AHPRA number (Australia)

Hear From The Experts

To view the highlights of ‘Advances in the Treatment of Acute Atrial Fibrillation’ webinar, click the link and enter your AHPRA number (Australia)